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In the obesogenic environment of the
twenty-first century, we need to focus fur-
ther scientific attention to design and im-
plement novel nutritional and pharmaco-
logic strategies aimed at our youngest
at-risk population in order to interrupt the
vicious cycle of obesity and diabetes risk.
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Figure 1. Diabetes Risk Can Begin during Prenatal Life
Intrauterine stressors, including maternal undernutrition or placental dysfunction (leading to impaired
blood flow, nutrient transport, or hypoxia) can initiate abnormal patterns of development and histonemod-
ification. Additional postnatal environmental factors, including accelerated postnatal growth, obesity, in-
activity, and aging can further contribute to DM risk, potentially via further histone modifications and DNA
methylation in critical tissues.
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The liver plays a central role in lipid and glucose metabolism. Two studies in this issue (Kubota et al., 2008;
Dong et al., 2008) on the insulin-signaling adaptors Irs1 and Irs2 prompt a critical reappraisal of the
physiology of fasting and of the integrated control of hepatic insulin action.Unlike other receptor tyrosine kinases,
insulin receptors grace the surface of tar-
get cells as preassembled heterodimers
and use adaptor proteins to activate
PI3K. The molecular cloning of these
adaptors, named insulin receptor sub-
strates (Irs), provided a cogent mechanis-tic and evolutionary explanation for the
divergence of insulin signaling from onco-
gene and growth-factor signaling. Irs pro-
teins carry out various functions down-
stream of insulin (and IGF) receptors by
(1) providing a juxtamembrane localiza-
tion signal for PIP3 generation, (2) amplify-Cell Meing the signal engendered by receptor
autophosphorylation, and (3) engaging a
panoply of substrates that account for
thediverse actions of insulin (White, 2003).
Phenotypic differences between differ-
ent Irs knockout mice ushered in the idea
that Irs play distinct roles in differenttabolism 8, July 2008 ª2008 Elsevier Inc. 7
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Previewstissues, downstream of insulin
versus IGF receptors. Irs1
knockouts are runted and
mildly insulin resistant, consis-
tent with a preferential role
downstream of IGF-1 recep-
tors; Irs2 knockouts develop
peripheral insulin resistance
and b cell failure, while knock-
outs of Irs3 or Irs4 displaymild
metabolic and growth pheno-
types (Nandi et al., 2004).
Although some phenotypic
variation can be explained
by differences in tissue distri-
bution (tissues with insulin-
dependent glucose uptake,
for example, express Irs1
and Irs3, with little Irs2), the
broader question of whether
there is functional overlap
or specificity in Irs1 versus
Irs2 signaling was largely
unsettled.
The Liver Conundrum
Nowhere was this issue more
prominent than in studies of liver insulin
action. Abnormalities of hepatic insulin ac-
tion—of the cell-autonomous and nonau-
tonomous varieties—play an important
role in the pathogenesis of type 2 diabe-
tes, nonalcoholic steatohepatitis, and
dyslipidemia.
In type 2 diabetes, hepatic insulin resis-
tance is associated with increased glu-
cose production (HGP) and ApoB-con-
taining lipoprotein secretion. The former
is arguably the cause of deteriorating glu-
cose control experienced by most dia-
betic patients over time, regardless of
therapy (Monnier et al., 2003). The latter
underpins thepredisposition toatheroscle-
rosis, which ultimately will be responsible
for nearly one in two deaths among dia-
betics (National Institute of Diabetes and
Digestive and Kidney Diseases, 2005).
But the two abnormalities can hardly be
subsumed under the common rubric of in-
sulin resistance. For while it’s increasingly
clear—and strongly supported by the
papers by Kubota et al. and Dong et al.
in this issue (Kubota et al., 2008; Dong
et al., 2008)—that an impairment of insulin
receptor signaling to Foxo1 can explain
insulin’s inability to restrain HGP, one
would predict that, if the liver were wholly
insulin resistant, triglyceride (TG) synthe-
sis and assembly into ApoB-containing
lipoproteins would also be impaired. But
the opposite is true in the diabetic liver.
In recent years, the idea that the dia-
betic liver may harbor a noxious brew of
insulin resistance and excessive insulin
sensitivity has gained a second wind.
The concept is neither new nor limited to
the liver. Several manifestations of insulin
resistance—e.g., polycystic ovarian dis-
ease and acanthosis nigricans—reflect
excessive rather than reduced insulin sig-
naling. But whereas in those tissues insu-
lin can act through IGF-1 receptors—if
blood insulin levels are high enough—he-
patocytes lack IGF-1 receptors, and thus
the explanation for the metabolic admix-
ture of sensitivity and resistance to insulin
in liver must reside within the different
branches of insulin receptor signaling.
In this context, several laboratories—
including ours—had proposed that dif-
ferent Irs proteins mediate different
branches of insulin signaling. The prevail-
ingmodel was that Irs1 presided over lipid
metabolism, whereas Irs2 presided over
HGP (Figure 1A).
The two papers in this issue (Kubota
et al., 2008; Dong et al., 2008) provide
a different explanation. Using conditional
knockouts of liver Irs1 and Irs2, the au-
thors demonstrate that the two proteins
play overlapping roles in insulin action,
with Irs1 acting in the post-
prandial state, and Irs2 in the
fasted state. The two sub-
strates are able to compen-
sate for one another, indicat-
ing that specificity of insulin
signaling arises downstream
of Irs proteins. Their actions
are funneled through tran-
scription factor Foxo1, further
establishing the latter’s role
as linchpin of insulin action.
Whither Hepatic Insulin
Resistance?
Several observations in these
papers will likely reshape our
thinking on metabolic disor-
ders. The branched pathway
model of insulin signaling, in
which Irs1 signals to lipid me-
tabolism and Irs2 to glucose
metabolism, is no longer ten-
able and should be aban-
doned (Figure 1b). The two
proteins are effectively inter-
changeable in relaying spe-
cific actions of insulin, as demonstrated
by the fact that individual knockouts of
Irs1 or Irs2 have little or no metabolic ef-
fect, while the combined knockouts result
in severe diabetes.
The Kubota paper shows that physio-
logically the two substrates take turns in
mediating insulin action, with Irs1 acting
as the housekeeping pathway and Irs2
picking up the slack during fasting and
early refeeding. But what is the need for
a dedicated insulin-signaling pathway
during fast, a time that should reflect
relative insensitivity to insulin? The most
obvious explanation is to preserve insulin
sensitivity in the face of changes in coun-
terregulatory hormones during the sleep-
wake cycle, nocturnal flux of FFAs from
adipose tissue, pulsatile insulin secretion,
or metabolic cues emanating from circa-
dian pacemakers. Bergman and others,
for example, documented the role of noc-
turnal flux of FFA to the liver in promoting
insulin resistance, arguably by impairing
insulin suppression of HGP (Bergman
and Ader, 2000). But in light of the Kado-
waki paper showing that insulin sensitivity
is maintained by Irs2 during fast, FFAs
could also provide grist for the lipogenic
mill, driving VLDL and LDL secretion,
and thus setting off the ill-starred combi-
nation of excessive glucose and lipid
Figure 1. The Changing Face of Hepatic Insulin Resistance
(A) The prevailing model had been that liver insulin signaling occurred by way
of branched pathways. One pathway, associated with Irs2 and Foxo1, was
thought to preside over the inhibition of glucose production (indicated by
a red ‘‘tee’’ symbol). The other pathway, mediated by Irs1 and Foxa2, was
thought to mediate lipid synthesis and lipoprotein assembly/secretion (indi-
cated by a thick green arrow).
(B) The work of Kubota et al. and Dong et al. supports a model in which Irs1 and
Irs2 act in different conditions (fasting or feeding), but in essentially linear path-
ways, both effected through Foxo1. The decrease in TG levels and secretion in
double Irsknockouts (denotedby thethingreen line,asopposed to thethickgreen
line in A) is consistent with a role of excessive insulin signaling, rather than insulin
resistance, in the pathogenesis of the lipid abnormalities of type 2 diabetes.8 Cell Metabolism 8, July 2008 ª2008 Elsevier Inc.
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Previewsproduction. Another clinical syndrome
that should be re-examined in light of
these new findings is impaired fasting glu-
cose (IFG), a widespread condition of un-
clear pathophysiology (Kim and Reaven,
2008). The reader should note that in
Dong et al. (but not in Kubota et al.), fast-
ing glucose levels inch up in Irs2 knock-
outs. Should we resequence the IRS2
gene in humans with IFG?
The Dog That Didn’t Bark
Dong et al.’s paper shows that lipid
metabolism is essentially normal (or im-
proved) in mice lacking hepatic Irs signal-
ing. It’s premature to conclude that insulin
resistance doesn’t affect lipid synthesis
and lipoprotein turnover, in view of oppo-
site findings indicating that hepatic insulin
receptor ablation is associated with in-
creased VLDL and ApoB levels (Biddinger
et al., 2008). More probing tests (in the
form of crosses onto atherosclerosis-
prone backgrounds) will have to be
conducted in the double Irs knockouts
to reach firmer conclusions. But, taken
at face value, the lipid data in the double
Irs knockout lend themselves to the inter-
pretation that excessive insulin signaling,
rather than insulin resistance, is responsi-
ble for hepatic dyslipidemia in type 2
diabetes. Given the growing calls for early
insulin treatment of type 2 diabetes
and the inevitable hyperinsulinemia that
goes with it, this problem is of great clini-cal and pharmacological relevance.
Should we protect the liver against exces-
sive insulinization? And is insulin treat-
ment partly to blame for the failure of
most glucose control regimens to signifi-
cantly abate the prevalence of macro-
vascular complications (UK Prospective
Diabetes Study Group, 1998)? As we
move into cardiovascular outcome-based
models to test the effects of diabetes
treatments, these questions acquire new
urgency.
Tangled No Longer: The Path to
Glucose Production
Dong observed that most of the gene
expression changes in the Irs1/Irs2 double
knockout couldbe reversedbyalsoknock-
ing out transcription factor Foxo1. These
data complement and expand work in
Drosophila and mice that had reached
similar, albeit less sweeping conclusions
(Gershman et al., 2007; Matsumoto et al.,
2007). A growing consensus points to
Foxo1 as the essential regulator of glucose
production in response to insulin. This is
not to say that there is nothing left tobedis-
covered. Among the outstanding ques-
tions are the following: the role of Foxo1
in lipidmetabolism, the nature of its regula-
tion in type 2 diabetes, and its interaction
with other components of the glucogenic
machinery (such as Torc2) and with
cAMP-dependent regulation of glycogen-
olysis/gluconeogenesis.Cell MeREFERENCES
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